[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100272246":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":46,"responsibleParty":77,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":40,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":40,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":49,"whyStopped":40,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exendin-(9-39)","EXPERIMENTAL","To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.",[13],"Drug: Exendin-(9-39)",{"label":15,"type":10,"description":16,"interventionNames":17},"Atropine","to evaluate the effect of neural activation on insulin secretion and glucose metabolism",[18],"Drug: Atropine",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.",[9],[25],"no other name for Exendin-(9-39)",{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.",[15],[30],"Atropine sulfate",[32],{"name":33,"affiliation":5,"role":34},"Marzieh Salehi, MD, MS","PRINCIPAL_INVESTIGATOR",[36,42],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Marzieh Salehi, MD MS","CONTACT","210-567-6691",null,"salehi@uthscsa.edu",{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},"Jennifer Foster, MSN","210-450-8696","fosterj6@uthscsa.edu",[47,67],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Texas Diabetes Institute - University Health System","RECRUITING","San Antonio","Texas","78207","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-98.49363,29.42412,{"lat":59,"lon":58},[62,65,66],{"name":63,"role":38,"phone":39,"phoneExt":40,"email":64},"Marzieh Salehi, MD","hansisdiarte@uthscsa.edu",{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},{"name":63,"role":34,"phone":40,"phoneExt":40,"email":40},{"facility":68,"status":49,"city":50,"state":51,"zip":69,"country":53,"countryCode":54,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"South Texas Veterans Health Care System","78229",{"type":56,"coordinates":71},[58,59],{"lat":59,"lon":58},[74,75,76],{"name":63,"role":38,"phone":39,"phoneExt":40,"email":41},{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},{"name":63,"role":34,"phone":40,"phoneExt":40,"email":40},{"type":78,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR",[80],{"name":81,"class":82},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100272246","early-phase-1-the-effects-of-bariatric-surgeries-on-glucose-metabolism-100272246",false,"NCT02823665","The Effects of Bariatric Surgeries on Glucose Metabolism","Inclusion Criteria:\n\n* Hypoglycemic RYGB patients with documented blood glucose level \\\u003C50 mg\u002Fdl\n* Asymptomatic individuals with bariatric surgery\n* Healthy non-surgical patients with no personal history of diabetes\n* Subjects must physically be able to come to our clinical research center Cedars-Sinai Medical Center\n\nExclusion Criteria:\n\n* Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \\\u003C11g\u002FdL); prisoners or institutionalized individuals; type 2 diabetes mellitis; development of any serious medical or psychiatric illness during recruitment or studies;\n* RYGB patients will be disqualified if they have gastric outlet obstruction or severe diarrhea.\n* Healthy non-surgical patients with personal history of diabetes\n\nFor administration of atropine, the following exclusions also apply:\n\n* History of glaucoma\n* Uncontrolled hypertension (any subjects with BP\\>140\u002F90 and history of dyslipidemia\n* Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)\n* Myasthenia gravis\n* Brain pathology\n* Enlarged prostate in men",true,"ALL","18 Years","65 Years",{"count":94,"type":95},200,"ESTIMATED","INTERVENTIONAL",[98],"EARLY_PHASE1","The purpose of this study is learn the effect of gastric bypass surgery and sleeve gastrectomy on glucose metabolism mediated by neural and hormonal factors initiated after eating.",[101,102,103,104],"Post Bariatric Surgery","Gastric Bypass","Sleeve Gastrectomy","Hypoglycemia After Gastric Bypass",[106,107,108,109],"gastric bypass surgery","Hypoglycemia","sleeve gastrectomy","glucose tolerance","2025-09-08",{"date":112,"type":113},"2025-09-09","ACTUAL",{"date":115,"type":40},"2015-07",{"date":117,"type":95},"2027-08",{"name":5,"class":6},2]